AACR Annual Meeting 2023
Satellite Educational Symposia

The Satellite Educational Symposia will be held in conjunction with the AACR Annual Meeting. These four CME-accredited events are supported by parties other than AACR and are not part of the official program of the AACR Annual Meeting. Symposia are evaluated by the Satellite Educational Symposia Committee to ensure that the educational content will enhance that provided by the official AACR scientific program.

Additional information will be available in Orlando at the specially marked counter located in the West Lobby C of the Convention Center.

A New Era of Early-Stage Cancer Care: A Think Tank Discussion on the Clinical Impact of Pathologic Response to Immunotherapy

Saturday, April 15, 2023
6:30 p.m.-9:00 p.m.
Grand Ballroom B, Rosen Centre Hotel

Join either in person or virtually for this live, 2-hour CME-certified satellite symposium featuring expert perspectives on the current state of pathologic response in the neoadjuvant setting, clinical evidence, application, and detail on putting it into practice with clinical cases and institutional workflows for multidisciplinary management. Bring your specific questions and converse with faculty during an interactive Q&A session.

Designing and Using Antibody-Drug Conjugates to Treat Solid Tumors

Saturday, April 15, 2023
6:30 p.m.-8:15 p.m.
Grand Ballroom A, Rosen Centre Hotel

• Registration and Dinner: 6:30 p.m.
• Program: 7:00 p.m.

The role of targeted therapy continues to expand in the oncology setting, with antibody-drug conjugates (ADCs) comprising one of the more recent advances for the management of solid tumors. Join us for our 75-minute, engaging symposium to learn more about the unique mechanism of action of these ADCs, the latest targets and advances, and clinical application of data from recent clinical trials in solid tumors. Our expert faculty will highlight key perspectives and strategies through didactic lecture, case presentations, and panel discussions. Expanded engagement is provided by an expert faculty member who will be available to interact directly with online audience members during the symposium and connect with interested participants for 30 minutes following the live event. All participants will be able to engage in interactive polling throughout the symposium.

In-person and virtual participation options.

The Advancing Role of PARP Inhibitor Combination Therapies to Improve Outcomes for Patients with mCRPC

Sunday, April 16, 2023
6:30 p.m.-8:30 p.m.
Grand Ballroom A, Rosen Centre Hotel

• Registration and Dinner: 6:30 p.m.
• Program: 7:00 p.m.

Recent clinical trial results with PARP inhibitors have demonstrated improvement in radiological progression-free survival and other parameters potentially offering new combination treatments when available. Synergistic combinations of PARP inhibitors and androgen receptor targeted therapy may become the new treatment paradigm for metastatic castration-resistant prostate cancer. Breakthroughs in genetic testing have led to the development of novel therapies that target the PARP pathway of DNA repair. Healthcare providers need to be current on the latest clinical trial data and clinical applications of emerging PARP inhibitor/androgen receptor combination therapies to inform clinical decision making. Please join our expert faculty as they discuss these research advances and place them within a practical and contemporary clinical context for developing and maintaining updated care pathways for persons suffering from advanced prostate cancer.

Targeting TROP2 and HER3: Perspective on the Next Precision Treatment Advances Across Solid Tumors

Sunday, April 16, 2023
6:30 p.m.-9:00 p.m.
Grand Ballroom B, Rosen Centre Hotel

• Registration: 6:30 p.m.
• Program: 7:00 p.m.

Join either in person or virtually for this live, 2-hour CME-certified symposium featuring an expert discussion of TROP2- and HER3-targeted antibody-drug conjugates and their current use in treating patients with solid tumors. Current data, ongoing trials, and potential use of targeted agents in NSCLC, breast cancer, and other types of tumors will be highlighted, along with interactive patient case scenarios and dynamic question and answer sessions.